CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Anna M. Pietroboni, Francesca Schiano Di Cola, Marta Scarioni, Chiara Fenoglio, Barbara Spanò, Andrea Arighi, Sara M.G. Cioffi, Emanuela Oldoni, Milena A. De Riz, Paola Basilico, Alberto Calvi, Giorgio G. Fumagalli, Fabio Triulzi, Daniela Galimberti, Marco Bozzali, Elio Scarpini

Research output: Contribution to journalArticle


Background: Neurodegeneration plays a major role in determining disability in multiple sclerosis (MS) patients. Hence, there is increasing need to identify reliable biomarkers, which could serve as prognostic measure of disease progression. Objectives: To assess whether cerebrospinal fluid (CSF) tau and β-amyloid (Aβ) levels were altered in newly diagnosed MS patients and correlated with disability. Moreover, we investigated whether these CSF biomarkers associate with macroscopic brain tissue damage measures. Methods: CSF Aβ and tau levels were determined by enzyme-linked immunosorbent assay in CSF samples from 48 newly diagnosed MS patients, followed-up clinically for 3 years by recording their Expanded Disability Status Scale score at 6-month intervals, and 45 controls. All patients underwent magnetic resonance imaging at baseline and at the end of follow-up to quantify their lesion load (LL). Results: CSF Aβ levels were significantly reduced in patients compared to controls (p < 0.001). Lower CSF Aβ levels at baseline were a disability predictor at 3-year follow-up (p = 0.009). CSF tau levels correlated with T2- and T1-LL (p < 0.001). Conclusion: CSF Aβ reduction is a promising biomarker of neurodegeneration and may predict patients' clinical outcome. Therefore, CSF Aβ should be considered as a potential biomarker of prognostic value.

Original languageEnglish
Pages (from-to)1085-1091
Number of pages7
JournalMultiple Sclerosis
Issue number8
Publication statusPublished - Jul 1 2017


  • beta-amyloid
  • biomarker
  • Multiple sclerosis
  • neurodegeneration
  • tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this